L K. Gowans
Expertise in
6
conditions

Dr. L K. Gowans

Pediatric Hematology Oncology
3571 West 13 Mile Road, Floor 2, 
Royal Oak, MI 
Clinical Trials:Currently Recruiting for 6 Trials
Accepting New Patients
Referral may be required
Before you request
Expertise in
6
conditions
3571 West 13 Mile Road, Floor 2, 
Royal Oak, MI 

Overview

L Gowans is a Pediatric Hematologist Oncology provider practicing medicine in Royal Oak, Michigan.

Dr. Gowans is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Ewing Sarcoma, Acute Lymphoblastic Leukemia (ALL), Osteosarcoma, Classical Hodgkin Lymphoma, and Bone Marrow Aspiration.

Dr. Gowans is board certified in American Board Of Pediatrics. She is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 42 clinical trials. Dr. Gowans is currently accepting new patients.

Specialties

Pediatric Hematology Oncology

Licenses

Pediatric Hematology-Oncology in MI

Board Certifications

American Board Of Pediatrics

Fellowships

University of WI Hospital & Clinics

Hospital Affiliations

Corewell Health William Beaumont University Hospital
Beaumont Hospital Royal Oak

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Longevity Health Plan
  • MEDICARE SNP
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 12 Less Insurance Carriers -

Locations

Corewell Health William Beaumont University Hospital Skandalaris Family Center for Children with Cancer & Blood Disorders - 3571 W 13 Mile Rd
3571 West 13 Mile Road, Floor 2, Royal Oak, MI 48073

Additional Areas of Focus

Dr. Gowans has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

42 Clinical Trials

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Enrollment Status: Recruiting
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Thioguanine, Vincristine Sulfate
Study Phase: Phase 2
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Other
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Radiation, Drug, Procedure
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Topotecan, Vincristine
Study Phase: Phase 2
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
View 4 Less Clinical Trials

1 Total Publications

Absence of human herpesvirus 6B detection in association with illness in children undergoing cancer chemotherapy.
Absence of human herpesvirus 6B detection in association with illness in children undergoing cancer chemotherapy.
Journal: Journal of medical virology
Published: January 24, 2016
Similar Doctors
Expertise in
1
conditions
Dr. Michala N. Burges
Pediatric Hematology Oncology
Expertise in
1
conditions
Dr. Michala N. Burges
Pediatric Hematology Oncology
Referral may be required
1500 E Medical Center Dr, 
Ann Arbor, MI 
 (33.1 miles away)
734-232-5933
Languages Spoken:
English

Michala Burges is a Pediatric Hematologist Oncology provider practicing medicine in Ann Arbor, Michigan. Dr. Burges is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Retinoblastoma.

Expertise in
7
conditions
Dr. Kaydee M. Kaiser
Pediatric Hematology Oncology
Expertise in
7
conditions
Dr. Kaydee M. Kaiser
Pediatric Hematology Oncology
Referral may be required
Before you request

Corewell Health William Beaumont University Hospital Skandalaris Family Center For Children With Cancer & Blood Disorders - 3571 W 13 Mile Rd

3571 West 13 Mile Road, Floor 2, 
Royal Oak, MI 
 (0.1 miles away)
248-551-0360
Experience:
10+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kaydee Kaiser is a Pediatric Hematologist Oncology provider practicing medicine in Royal Oak, Michigan. She has been practicing medicine for over 10 years. Dr. Kaiser is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Ewing Sarcoma, Febrile Neutropenia, and Primary Mediastinal B-Cell Lymphoma (PMBCL). Dr. Kaiser is board certified in American Board Of Pediatrics. Dr. Kaiser is currently accepting new patients.

Expertise in
5
conditions
Dr. Marie V. Nelson
Pediatric Hematology Oncology
Expertise in
5
conditions
Dr. Marie V. Nelson
Pediatric Hematology Oncology
Referral may be required
Before you request

Corewell Health William Beaumont University Hospital Skandalaris Family Center For Children With Cancer & Blood Disorders - 3571 W 13 Mile Rd

3571 West 13 Mile Road, Floor 2, 
Royal Oak, MI 
 (0.1 miles away)
248-551-0360
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Marie Nelson is a Pediatric Hematologist Oncology provider practicing medicine in Royal Oak, Michigan. Dr. Nelson is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Ewing Sarcoma, Neuroblastoma, Acute Lymphoblastic Leukemia (ALL), and Osteosarcoma. Dr. Nelson is board certified in American Board Of Pediatrics. Dr. Nelson is currently accepting new patients.

Frequently Asked Questions about Dr. L K. Gowans

How do I make an appointment with Dr. L K. Gowans?

You can book an appointment with Dr. L K. Gowans by calling their office at 248-551-0360. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. L K. Gowans a top-rated expert for Ewing Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. L K. Gowans is classified as an Advanced expert for Ewing Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. L K. Gowans specialize in?

While Dr. L K. Gowans is a Pediatric Hematology Oncology, they have specific expertise in Ewing Sarcoma, Acute Lymphoblastic Leukemia (ALL), and Osteosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatric Hematology Oncology.

Does Dr. L K. Gowans participate in research or clinical trials?

Yes. Dr. L K. Gowans has published 1 articles and abstracts on conditions like Ewing Sarcoma. You can view a list of Dr. L K. Gowans's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. L K. Gowans accept my insurance?

Dr. L K. Gowans accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 248-551-0360 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gowans's expertise for a condition
ConditionClose
      View All 36 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile